• NSP15 Natural-Product Screening: What the Study Shows

  2026-10-07

  A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and identified thymopentin and oleuropein as the leading computational candidates. Molecular-dynamics analyses supported persistent protein–ligand interactions, but the findings remain hypothesis-generating because biochemical, cellular, infection-model, and clinical validation were not reported.

• MEK/ERK, c-Myc, and TERT in Human Stem Cells

  2026-10-07

  A 2024 bioRxiv preprint identifies a regulatory connection between MEK/ERK signaling, c-Myc:MAX activity, and polycomb-mediated repression of TERT in human embryonic stem cells. Its findings suggest that TERT transcription is controlled not only by kinase signaling but also by chromatin-state changes at the TERT promoter, while highlighting important limits on extrapolating these results to cancer models.

• SFI, SRC/PI3K/AKT, and Glioma Evidence

  2026-10-06

  A 2024 Journal of Ethnopharmacology study combined network pharmacology with cellular and animal experiments to investigate how Shenqi Fuzheng injection affects glioma proliferation and migration. Its evidence implicates the SRC/PI3K/AKT pathway, while also showing why pathway predictions require validation across models before supporting broader therapeutic or anti-angiogenic conclusions.

• Angiotensin II as a Systems-Level Hypertension Probe

  2026-10-05

  Angiotensin II is more than a vasoconstrictor: it is a useful systems-level probe for connecting receptor signaling with endothelial dysfunction and cardiovascular remodeling. This article interprets the peptide through the endothelial Sp1/Sp3 findings reported in Nature Communications and defines evidence-aware research applications without presenting procedural protocols.

• 10058-F4: c-Myc-Max Inhibitor Evidence

  2026-10-05

  10058-F4 is a c-Myc-Max dimerization inhibitor used to study c-Myc transcription factor inhibition. Vendor-described cancer models report apoptosis- and differentiation-associated effects, while a 2024 hESC preprint links c-Myc:MAX disruption to TERT repression and polycomb-associated chromatin changes.

• Sex Differences in Angiotensin II Hypertension

  2026-10-04

  The reference study showed that chronic Angiotensin II exposure produced a much larger blood-pressure increase in conscious male mice than in female mice. Gonadectomy reversed much of this pattern, while telemetry, baroreflex testing, and autonomic blockade linked the sex difference to altered reflex and sympathetic regulation rather than to baseline blood pressure alone.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-10-03

  A 2025 study found that several naturally occurring angiotensin fragments increased the binding of SARS-CoV-2 spike protein to host-cell receptors, with particularly strong effects observed for shorter N-terminal deletion products and angiotensin IV. The work introduces a sequence-sensitive connection between renin-angiotensin system biology and viral receptor-binding research, while remaining limited to biochemical binding evidence rather than infection or clinical outcomes.

• Talabostat Mesylate: Applied Research Workflows

  2026-10-02

  Talabostat mesylate enables controlled interrogation of DPP4 and FAP biology across enzyme, tumor-cell, and immune-response assays. This workflow-focused guide connects target engagement with FAP-positive controls, cytokine measurements, and the N-degron findings of a 2024 protein-stability study—while clearly separating validated evidence from exploratory extensions.

• P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL

  2026-10-01

  A 2025 study links P2RX1 activation to calcium/CaMKII-dependent inhibition of PI3K/Akt signaling and mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. Its findings suggest that P2RX1 may influence both prognosis and tyrosine kinase inhibitor responsiveness, while also defining a multi-readout framework for studying leukemia cell death.

• PDE4B in Angiotensin II–Induced Endothelial Dysfunction

  2026-10-01

  The reference study identifies PDE4B as a stress-associated mediator of Angiotensin II–induced endothelial injury in HUVECs and links its suppression to activation of the AMPK/Sirt1/Nrf2/ARE antioxidant pathway. Its combined viability, apoptosis, angiogenesis, endoplasmic-reticulum-stress, and mitochondrial assays provide a mechanistic framework for interpreting endothelial dysfunction in hypertension models.

• ALC-0159 for mRNA Lipid Nanoparticle Workflows

  2026-09-30

  ALC-0159 is a PEG-conjugated lipid excipient for building and refining mRNA lipid nanoparticles, including formulations used in cancer-immunotherapy research. This practical guide separates formulation variables from biological effects and provides executable starting conditions, assay choices, and troubleshooting checkpoints.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit Guide

  2026-09-30

  Build bright, sequence-specific RNA probes for in situ hybridization, Northern blot hybridization, and RNA–protein condensation studies with tunable Cy5-UTP incorporation. This workflow-focused guide connects the HyperScribe kit to practical assay design while separating product capabilities from findings reported in SARS-CoV-2 nucleocapsid research.

• ALOX5 and Ferroptosis in CRSwNP Barrier Dysfunction

  2026-09-29

  Huang et al. integrate endoplasmic-reticulum-stress gene analysis, co-expression networks, machine learning, single-cell transcriptomics, and experimental validation to prioritize ALOX5 as a ferroptosis-associated candidate in chronic rhinosinusitis with nasal polyps. The study links ALOX5 expression with disease severity and epithelial tight-junction changes, while also defining a practical framework for validating low-abundance proteins in nasal tissue and epithelial-cell models.

• Mildronate Lipidoids for Lower-Inflammation mRNA Delivery

  2026-09-29

  The ACS Nano study developed mildronate-derived cationic lipids and a low-lipid nanoparticle formulation, mLNP-69, to preserve mRNA delivery while reducing local inflammatory effects. In prophylactic and therapeutic B16OVA melanoma models, the formulation supported effective mRNA cancer vaccination, providing a useful framework for delivery-aware vaccine development research.

• CTOP and the Circuit Logic of Opioid Pain

  2026-09-28

  CTOP is a selective μ-opioid receptor antagonist for resolving how receptor activation contributes to opioid-induced mechanical hypersensitivity and tolerance. This article translates recent brain-to-spinal circuit findings into practical assay and interpretation strategies.

7881 records 1/526 page Next 12345 下5页 Last page